Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment

Neuroscience
F I TaraziI Creese

Abstract

Changes in dopamine receptor subtype binding in different brain regions were examined after 28 days treatment of rats with haloperidol, raclopride, clozapine or SCH23390 using in vitro receptor autoradiography. [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin binding to dopamine D3 receptors was not changed in any brain region by any of the drug treatments. [3H]SCH23390 was only increased by chronic SCH23390 treatment. Haloperidol significantly increased [3H]nemonapride and [3H]spiperone binding to dopamine D2-like receptors in the caudate putamen. In contrast, haloperidol caused a small, significant increase in [3H]raclopride binding in the lateral caudate putamen only. Raclopride also elevated, but to a lesser extent [3H]nemonapride and [3H]spiperone binding in caudate putamen, whereas it did not affect [3H]raclopride binding. Clozapine did not significantly change D2-like striatal binding of [3H]nemonaipride, [3H]spiperone or [3H]raclopride. The differences in radioligand binding suggest that [3H]nemonapride and [3H]spiperone may be binding to additional subsets of dopamine D2-like receptors (including D4-like receptors) that are not recognized by [3H]raclopride, which has high affinity for D2 and D3 receptors only. Quantificat...Continue Reading

References

May 15, 1978·European Journal of Pharmacology·I Creese, S H Snyder
Oct 22, 1992·Neuroscience Letters·J H Meador-WoodruffS J Watson
Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueP Sokoloff
Feb 11, 1992·Trends in Pharmacological Sciences·D R Sibley, F J Monsma
Jan 1, 1991·Journal of Neural Transmission. General Section·R C Arora, H Y Meltzer
Jul 1, 1990·Trends in Neurosciences·G E Alexander, M D Crutcher
Oct 1, 1990·Trends in Pharmacological Sciences·J HietalaE Syvälahti
Oct 1, 1989·Trends in Neurosciences·R L AlbinJ B Penney
Feb 1, 1989·Trends in Pharmacological Sciences·L Vallar, J Meldolesi
Feb 12, 1985·European Journal of Pharmacology·I Creese, A Chen
Aug 1, 1988·Naunyn-Schmiedeberg's Archives of Pharmacology·C A AltarP L Wood
Dec 3, 1985·European Journal of Pharmacology·M L PorcedduG Biggio
Aug 4, 1995·European Journal of Pharmacology·G P Reynolds, S L Mason
Jan 5, 1995·European Journal of Pharmacology·A M Gonzalez, D R Sibley
Mar 15, 1995·European Journal of Pharmacology·O SchootsH H Van Tol
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueJ C Schwartz
Oct 1, 1994·Journal of Neurochemistry·G P Reynolds, S L Mason
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·M S Lidow, P S Goldman-Rakic

❮ Previous
Next ❯

Citations

Mar 20, 2010·Neurotoxicity Research·Trevor ArcherRichard M Kostrzewa
Oct 18, 2000·European Journal of Pharmacology·J N OakH H Van Tol
Jun 23, 2001·Pharmacology, Biochemistry, and Behavior·K ZhangR J Baldessarini
May 22, 2003·Pharmacology, Biochemistry, and Behavior·Michael R DrewPeter D Balsam
Mar 17, 2000·Brain Research. Brain Research Reviews·J C SchwartzP Sokoloff
Sep 28, 1998·Brain Research. Developmental Brain Research·F I TaraziR J Baldessarini
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·F I TaraziR J Baldessarini
Aug 8, 1998·Neuroscience Letters·F I TaraziR J Baldessarini
Mar 10, 2000·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·F I Tarazi, R J Baldessarini
Jul 27, 2001·Journal of Chemical Neuroanatomy·Y L HurdG C Sedvall
Sep 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F I TaraziJ L Neumeyer
Jan 14, 1998·Neuroreport·F I TaraziR J Baldessarini
Sep 12, 2008·Human & Experimental Toxicology·K HeardN R Zahniser
Sep 3, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jiamei LianChao Deng
Nov 16, 2013·CNS Spectrums·Yong Kee ChoiFrank I Tarazi
Mar 26, 2011·Purinergic Signalling·Maria Letizia TrincavelliClaudia Martini
Jan 4, 2012·L'Encéphale·E FakraJ-M Azorin
May 24, 2011·Neuroscience and Biobehavioral Reviews·Heather C Brenhouse, Susan L Andersen
Mar 21, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M Laruelle
Aug 21, 2007·Brain Research·Marina Sorrentino HernandesLanfranco Ranieri Paolo Troncone
Jun 21, 2007·Human Psychopharmacology·Georges BrousseBernard Lachaux
May 14, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Rae PriceTarek K Rajji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here